title: Ondansetron reduces the incidence and severity of poststrabismus repair vomiting in children.
abstract: This prospective, randomized, placebo-controlled, double-blinded study evaluated the antiemetic efficacy of ondansetron and metoclopramide in 90 ASA physical status I or II children, 2-17 yr of age, undergoing strabismus repair. After anesthetic induction and prior to eye muscle manipulation, subjects received normal saline 0.3 mL/kg (Group 1), metoclopramide 0.25 mg/kg (Group 2), or ondansetron 0.15 mg/kg (Group 3), intravenously. There were no differences between groups with respect to age, weight, gender, fluids received, number of eye muscles repaired, anesthetic technique, or time in the operating room. The incidence of vomiting in Groups 1, 2, and 3 was 50%, 27%, and 10% prior to discharge, and 67%, 53%, and 30% during the 24 h after surgery, respectively. The number of children vomiting prior to discharge and within 24 h of surgery was significantly reduced in Group 3 compared with Group 1 (P < 0.003 and P < 0.015, respectively). The number of vomiting episodes per patient in Groups 1, 2, and 3 was 1.1, 0.5, and 0.1 prior to discharge, and 4.5, 2.6, and 1.2 during the 24 h after surgery (P < 0.0005 and P < 0.004, respectively). Ondansetron 0.15 mg/kg intravenously after the induction of anesthesia reduces the incidence and severity of vomiting after strabismus repair both prior to discharge from the hospital and during the 24 h after surgery.
authors.affiliation: Department of Anesthesiology, Alfred I. duPont Institute, Wilmington, Delaware 19899.
authors.forename: J B
authors.initials: JB
authors.lastname: Rose
authors.forename: T M
authors.initials: TM
authors.lastname: Martin
authors.forename: D H
authors.initials: DH
authors.lastname: Corddry
authors.forename: M
authors.initials: M
authors.lastname: Zagnoev
authors.forename: R G
authors.initials: RG
authors.lastname: Kettrick
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D013285:Strabismus / Q000601:surgery*; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D017294:Ondansetron